Medprin plans to acquire 100% equity of Yijie Medical, whose main business is in the field of neurology and vascular interventional medical devices

According to the Zhitong Finance APP, Medprin (301033.SZ) disclosed a plan for issuing shares and paying cash to purchase assets and raise supporting funds, as well as related party transactions. The company intends to purchase 100% equity of Yijie Medical from ZeXin Medical and 10 other trading parties through the issuance of shares and cash payment, while raising supporting funds. The issuance price for shares to purchase assets is set at RMB 41.40 per share, and the issuance price for raising supporting funds is set at RMB 48.03 per share.

The amount of supporting funds raised will not exceed 100% of the transaction price for the share issuance to purchase assets, and the number of shares issued will not exceed 30% of the company's total share capital before the issuance of supporting funds.

According to the announcement, the target company mainly engages in the research and development, design, and sales of vascular interventional medical devices in the field of neurology, with main products including neurointerventional catheters, neurointerventional guidewires, and balloon dilation catheters. After the completion of this transaction, the listed company will further expand its product categories and form a diversified product matrix.

In addition, the company will resume trading on June 6, 2025 (Friday) at the market opening